

2nd REGIONAL HIVAS CONGRESS

3 – 4 December 2021

FINAL PROGRAM

FRIDAY 03.12.2021

13.50 – 14.00	OPENING CEREMONY Jovan Ranin, HIVAS president Message from President of EACS dr Sanjay Bhagani	
14.00 – 15.40	HIVAS INTERACTIVE COURSE - Learning through experience Coordinator: Danijela Marić Moderators: Ana Milinković, Mark Youle	
	HIV testing – modalities and challenges	
14.00 – 14.05	<i>Tomislav Vlaški (Serbia)</i>	NS Check point - first rapid testing site in Vojvodina
14.05 – 14.10	<i>Aleksandra Bulović (Serbia)</i>	Self assessment of risk for acquiring HIV
14.10 – 14.15	<i>Jelena Đurica (Serbia)</i>	Selfinitiated HIV testing – what more can we do?
14.15 – 14.20	<i>Vanja Boljanović (Serbia)</i>	Symptomatic HIV patient testing – why and when is HIV testing done
	HIV in women and children	
14.20 – 14.25	<i>Danijela Praštalo (Serbia)</i>	Perinatal HIV transmission – case presentation
	Opportunistic infections and tumours	
14.25 – 14.40	<i>Sofija Sekulić Marković (Serbia)</i>	Spleen abscess in a patient with HIV
14.40 – 14.45	<i>Nevena Todorović (Serbia)</i>	Opportunistic and respiratory infections and COVID-19 in newly diagnosed HIV patients – case report
14.45 – 14.55	<i>Maja Drljača (Serbia)</i>	CNS toxoplasmosis – case presentation
14.55 – 15.00	<i>Tijana Čukić (Serbia)</i>	Amaebic colitis – case presentation
	ChemSex	
15.00 – 15.10	<i>Vanja Andrić (Serbia)</i>	ChemSex in Serbia - preliminary results of an online survey
15.10 – 15.40	DISCUSSION	
15.40 – 16.00	BREAK	

16.00 – 19.20	SESSION 1 EPIDEMIOLOGICAL ASPECTS OF HIV INFECTION Coordinators: Šime Zekan, Blaž Pečavar	
16.00 – 16.20	<i>Barbara Kokošar & SHIVA (Slovenija)</i>	People living with HIV in Slovenia: National overview
16.20 – 16.40	<i>Brankica Dupanović (Montenegro)</i>	TBA
16.40 – 17.00	<i>Blaž Pečavar & SHIVA (Slovenia)</i>	Slovenian PrEP demonstration project
17.00 – 17.20	<i>Šime Zekan (Croatia)</i>	PrEP in Croatia - 3 years of experience - lessons learned and future plans
17.20 – 17.40	<i>Vesna Hadžiosmanović (BiH)</i>	The role of PrEP in the HIV prevention strategy in SUCC
17.40 – 18.00	<i>Danijela Marić (Serbia)</i>	PrEP TaskForce - obstacles and possible solutions for PrEP in Serbia
18.00 – 18.20	<i>Danijela Simić (Serbia)</i>	Characteristics of the HIV epidemic in the Republic of Serbia at the end of 2020
18.20 – 18.40	<i>Velimir Saveski (North Macedonia)</i>	Introduction of pre-exposure prophylaxis (PrEP) for HIV in North Macedonia
18.40 – 19.00	<i>Mila Paunić (Serbia)</i>	Modalities of HIV testing - experiences from the Student Polyclinic Belgrade
19.00 – 19.40	DISCUSSION	

SATURDAY 4.12.2021

SESSION 2 VIROLOGICAL-IMMUNOLOGICAL ASPECTS OF HIV INFECTION		
09.00 – 11.30		
Coordinators: Jovan Ranin, Gordana Dragović		
09.00 – 09.20	<i>Jovan Ranin (Serbia)</i>	Possible outcomes of HIV infection
09.20 – 09.40	<i>Josip Begovac (Croatia)</i>	From HIV diagnosis to undetectable viral load, Croatia 2015-2020
09.40 – 10.00	<i>Tomaž Vovko, Maja M. Lunar, Mario Poljak (Slovenia)</i>	Transmitted and acquired HIV drug resistance in a Slovenian cohort of patients from 2011 to 2020
10.00 – 10.20	<i>Gordana Dragović (Serbia)</i>	Telomere shortening in HIV-aging patients
10.20 – 10.40	<i>Božana Obradović (Serbia)</i>	Analysis of CYP3A4, CYP2B6 and ABCB1 polymorphism in Belgrade HIV cohort
10.40 – 11.00	<i>Manja Kordiš & all. (Slovenia)</i>	The role of HIV-1 infection on the composition of blood endovesicles
11.00 – 11.30	DISCUSSION	

SESSION 3 CLINICAL ASPECTS OF HIV INFECTION		
11.30 – 14.50		
Coordinators: Jurgen Rockstroh, Janez Tomažič		
11.30 – 11.50	<i>Jürgen Rockstroh (Germany)</i>	Late presentation in HIV: still a problem?
11.50 – 12.10	<i>Ana Milinković (UK)</i>	Comorbidities in PLWHIV
12.10 – 12.30	<i>Jürgen Rockstroh (Germany)</i>	Weight gain under ART: is this a real problem?
12.30 – 12.50	<i>Biljana Popovska-Jovičević (Serbia)</i>	HIF-1A in patients with HIV infection
12.50 – 13.10	<i>Janez Tomažič & all. & SHIVA (Slovenia)</i>	Assessment of the COVID-19 vaccination effectiveness in Slovenian HIV infected population
13.10 – 13.30	<i>Mike Youle (UK)</i>	Syphilis in the time of COVID and other STDs
13.30 – 13.50	<i>Biljana Petreska (North Macedonia)</i>	COVID-19 in patients with HIV infection in North Macedonia
13.50 – 14.10	<i>Marko Marković (Serbia)</i>	HIV and COVID in Serbia
14.10 – 14.40	DISCUSSION	
14.40 – 14.50	BREAK	

SESSION 4 MODERN PRINCIPLES OF HIV INFECTION TREATMENT Coordinators: Snežana Brkić, Mark Nelson, Ana Milinković		
14.50 – 19.00		
14.50 – 15.10	Jürgen Rockstroh (Germany)	State of the art of ART therapy in HIV or New drugs for HIV therapy: Do we really need them?
15.10 – 15.30	Mark Nelson (UK)	2DRs
15.30 – 15.50	Christoph Boesecke (Germany)	State of the art of ART therapy in HIV or New drugs for HIV therapy: Do we really need them?
15.50 – 16.10	Manja Kordiš & all. (Slovenia)	Assessment of early markers of cardiovascular risk in HIV-1 infected patients on stable therapy.
16.10 – 16.30	DISCUSSION	
16.30 – 17.20	Company symposia MEDICOPHARMACIA	
16.30 – 16.50	Daniela Marić (Serbia)	Comorbidities of people living with HIV and the place of Biktarvy in the treatment of PLWH
16.50 – 17.10	Miodrag Dikić (Serbia)	The importance of considering the lipid profile of the patient when choosing ARV therapy
17.10 – 17.20	DISCUSSION	
17.20 – 18.10	Company symposia Janssen	
17.20 – 17.30	Jovan Ranin (Serbia)	HIV treatment goals and recommendations
17.30 – 17.45	Snežana Brkić (Serbia)	Symtuza- Single tablet with many opportunities for HIV treatment
17.45 – 18.00	Marko Marković (Serbia)	Role of Symtuza in HIV treatment practice in Serbia
18.00 – 18.10	DISCUSSION	
18.10 – 19.00	Company symposia GSK	
18.10 – 18.50	José M. Gatell (Spain)	TBD
18.50 – 19.00	DISCUSSION	
19.00 – 20.20	SESSION 4-b MODERN PRINCIPLES OF HIV INFECTION TREATMENT Coordinators: Snežana Brkić, Mark Nelson, Ana Milinković	
19.00 – 19.20	Snežana Brkić (Serbia)	A practical approach to treatment optimization
19.20 – 19.40	Mirjana Šefik Bukilica (Serbia)	Osteoporosis Screening in HIV
19.40 – 20.00	Ljiljana Popović (Serbia)	Metabolic syndrome in people with HIV in the light of new recommendations for the prevention of cardiovascular disease
20.00 – 20.20	DISCUSSION	
20.20 – 20.30	CLOSING CEREMONY	